The first-ever treatment guidelines for systemic Sjogren’s syndrome have been issued highlighting the need to alleviate symptoms, improve quality of life and prevent further damage.
The Sjogren’s Syndrome Foundation has issued the first-ever treatment guidelines for systemic Sjogren’s syndrome, a disease that affects as many as 6 million people in the U.S. with or without connective tissue disease.
Sjogren’s syndrome is one of the most difficult chronic autoimmune rheumatic disorders to treat, wrote the authors of the recommendations that appear in the March 2017 print issue of Arthritis Care & Research. “It is difficult to distinguish between disease activity and damage, and therefore it is challenging to identify active cases to achieve a meaningful response,” the authors wrote.
Because there is no-known cure, the treatment recommendations are designed to alleviate symptoms, improve quality of life, prevent further damage and help physicians select the appropriate immunosuppressive treatment for patients.
Led by Steven E. Carsons, M.D., of Winthrop University Hospital in Mineola, New York, the physician committee outlined 19 recommendations which center on the use of biologic agents, the management of fatigue and inflammatory musculoskeletal pain.
The guidelines are comprehensive, so here, we highlight some important points:
Rituximab uses in Sjogren’s syndrome:
Other important findings:
Development of the guidelines was done with support from the Sjogren’s Syndrome Foundation.
Steven E. Carsons, Frederick B. Vivino, Ann Parke, et al. “Treatment Guidelines for Rheumatologic Manifestations of Sj€ogren’s Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain,” Arthritis Care & Research. March 2017. DOI 10.1002/acr.22968